Bak is significantly upregulated in tumor tissues isolated from genetically engineered LSL-KRASG12D LKB1fl/fl (KL) mice, further supporting BKA-073, a Bak agonist, as an ideal agent for treatment of KRAS-driven lung cancer. Here, BAK1 is linked to lung carcinoma.